FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111897685> ?p ?o ?g. }

• W2111897685 endingPage "427" @default.
• W2111897685 startingPage "420" @default.
• W2111897685 abstract "This study was designed to determine the efficacy and toxicity of weekly docetaxel in metastatic breast cancer when given alone (for HER2/neu—negative disease) or with trastuzumab (for HER2/neu—overexpressing disease). Patients with metastatic breast carcinoma received docetaxel given on 2 different schedules (group 1A, 33 mg/m2 weekly [n = 21]; group 1B, 40 mg/m2 weekly for 3 weeks with 1 week off [n = 14]). Patients with HER2/neu—overexpressing disease also received trastuzumab 4 mg/kg on day 1, then 2 mg/kg on days 8 and 15 of each 28-day cycle (group 2). Fifty-two patients were treated with docetaxel alone (group 1A/B, n = 35) or in combination with trastuzumab (group 2, n = 17). Prior taxane therapy given every 3 weeks had been used for metastatic disease in 19 of 35 patients (54%) in group 1A/B and in 2 of 17 patients (12%) in group 2. The mean delivered dose intensity of docetaxel was 29 mg/m2 per week. Partial response occurred in 7 of 35 patients (21%; 95% exact binomial confidence interval [CI], 9%-38%) treated with docetaxel alone, including 3 of 19 taxane-pretreated patients (16%) and 4 of 16 taxane-naive patients (25%). Partial response occurred in 10 of 17 patients (59%; 95% CI, 34%-82%) treated with docetaxel/trastuzumab. The most common grade 3/4 toxicities, occurring in = 10% of patients, included neutropenia (21%), pulmonary toxicity (12%), and hyperglycemia (10%). The median times to disease progression were 4.5 months (95% CI, 2.5- 6.5 months) in the docetaxel group and 8.5 months (95% CI, 4.5-12.5 months) in the docetaxel/trastuzumab group. Weekly docetaxel/trastuzumab is an effective regimen for patients with HER2/neu—overexpressing metastatic breast cancer. Weekly docetaxel may be effective in as many as 20% of patients who had progressive disease after treatment with taxanes given every 3 weeks." @default.
• W2111897685 created "2016-06-24" @default.
• W2111897685 creator A5011233983 @default.
• W2111897685 creator A5028468010 @default.
• W2111897685 creator A5040980438 @default.
• W2111897685 creator A5068839570 @default.
• W2111897685 creator A5083685277 @default.
• W2111897685 creator A5083912691 @default.
• W2111897685 creator A5084480086 @default.
• W2111897685 creator A5085623893 @default.
• W2111897685 creator A5085875361 @default.
• W2111897685 date "2004-02-01" @default.
• W2111897685 modified "2023-09-23" @default.
• W2111897685 title "Phase II Study of Weekly Docetaxel Alone or in Combination with Trastuzumab in Patients with Metastatic Breast Cancer" @default.
• W2111897685 cites W118663861 @default.
• W2111897685 cites W1586319475 @default.
• W2111897685 cites W1603672218 @default.
• W2111897685 cites W1760955494 @default.
• W2111897685 cites W1841504999 @default.
• W2111897685 cites W1846747462 @default.
• W2111897685 cites W1920828316 @default.
• W2111897685 cites W1955744924 @default.
• W2111897685 cites W1981161601 @default.
• W2111897685 cites W2000433012 @default.
• W2111897685 cites W2003710931 @default.
• W2111897685 cites W2018791660 @default.
• W2111897685 cites W2022915103 @default.
• W2111897685 cites W2076668534 @default.
• W2111897685 cites W2085527076 @default.
• W2111897685 cites W2085765986 @default.
• W2111897685 cites W2094627540 @default.
• W2111897685 cites W2115759102 @default.
• W2111897685 cites W2121247384 @default.
• W2111897685 cites W2135222080 @default.
• W2111897685 cites W2141056749 @default.
• W2111897685 cites W2141393790 @default.
• W2111897685 cites W2144661279 @default.
• W2111897685 cites W2146406055 @default.
• W2111897685 cites W2149051430 @default.
• W2111897685 cites W2159459001 @default.
• W2111897685 cites W2161714684 @default.
• W2111897685 cites W2228069427 @default.
• W2111897685 cites W2318605753 @default.
• W2111897685 cites W4293241248 @default.
• W2111897685 cites W4322702492 @default.
• W2111897685 doi "https://doi.org/10.3816/cbc.2004.n.005" @default.
• W2111897685 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15023243" @default.
• W2111897685 hasPublicationYear "2004" @default.
• W2111897685 type Work @default.
• W2111897685 sameAs 2111897685 @default.
• W2111897685 citedByCount "35" @default.
• W2111897685 countsByYear W21118976852012 @default.
• W2111897685 countsByYear W21118976852013 @default.
• W2111897685 countsByYear W21118976852014 @default.
• W2111897685 countsByYear W21118976852015 @default.
• W2111897685 countsByYear W21118976852018 @default.
• W2111897685 crossrefType "journal-article" @default.
• W2111897685 hasAuthorship W2111897685A5011233983 @default.
• W2111897685 hasAuthorship W2111897685A5028468010 @default.
• W2111897685 hasAuthorship W2111897685A5040980438 @default.
• W2111897685 hasAuthorship W2111897685A5068839570 @default.
• W2111897685 hasAuthorship W2111897685A5083685277 @default.
• W2111897685 hasAuthorship W2111897685A5083912691 @default.
• W2111897685 hasAuthorship W2111897685A5084480086 @default.
• W2111897685 hasAuthorship W2111897685A5085623893 @default.
• W2111897685 hasAuthorship W2111897685A5085875361 @default.
• W2111897685 hasConcept C121608353 @default.
• W2111897685 hasConcept C126322002 @default.
• W2111897685 hasConcept C143998085 @default.
• W2111897685 hasConcept C2775930923 @default.
• W2111897685 hasConcept C2776694085 @default.
• W2111897685 hasConcept C2777063308 @default.
• W2111897685 hasConcept C2777511904 @default.
• W2111897685 hasConcept C2779786085 @default.
• W2111897685 hasConcept C2781190966 @default.
• W2111897685 hasConcept C530470458 @default.
• W2111897685 hasConcept C71924100 @default.
• W2111897685 hasConcept C90924648 @default.
• W2111897685 hasConceptScore W2111897685C121608353 @default.
• W2111897685 hasConceptScore W2111897685C126322002 @default.
• W2111897685 hasConceptScore W2111897685C143998085 @default.
• W2111897685 hasConceptScore W2111897685C2775930923 @default.
• W2111897685 hasConceptScore W2111897685C2776694085 @default.
• W2111897685 hasConceptScore W2111897685C2777063308 @default.
• W2111897685 hasConceptScore W2111897685C2777511904 @default.
• W2111897685 hasConceptScore W2111897685C2779786085 @default.
• W2111897685 hasConceptScore W2111897685C2781190966 @default.
• W2111897685 hasConceptScore W2111897685C530470458 @default.
• W2111897685 hasConceptScore W2111897685C71924100 @default.
• W2111897685 hasConceptScore W2111897685C90924648 @default.
• W2111897685 hasIssue "6" @default.
• W2111897685 hasLocation W21118976851 @default.
• W2111897685 hasLocation W21118976852 @default.
• W2111897685 hasOpenAccess W2111897685 @default.
• W2111897685 hasPrimaryLocation W21118976851 @default.
• W2111897685 hasRelatedWork W1971716849 @default.
• W2111897685 hasRelatedWork W2014205823 @default.
• W2111897685 hasRelatedWork W2050605839 @default.

• next